Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (171-180 of 520) with videos related to

Pageof 52
Sort By:
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Circulation|December 1, 2004
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) studyMariya P Tokmakova, Hicham Skali, Satish Kenchaiah, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|September 29, 2005
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM ProgramGary F Mitchell, J Malcolm O Arnold, Mark E Dunlap, et al.
European Journal of Heart Failure|March 1, 2014
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRTHicham Skali, Edward M Dwyer, Robert Goldstein, et al.
The American Journal of Cardiology|March 25, 2008
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitusNagesh S Anavekar, Scott D Solomon, John J V McMurray, et al.
European Journal of Heart Failure|October 1, 2022
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Brian L Claggett, Orly Vardeny, et al.
Hypertension (Dallas, Tex. : 1979)|December 12, 2007
Aortic diameter, wall stiffness, and wave reflection in systolic hypertensionGary F Mitchell, Paul R Conlin, Mark E Dunlap, et al.
NEJM Evidence|August 30, 2023
Quantifying Treatment Effects in Trials with Multiple Event-Time OutcomesBrian Lee Claggett, Zachary R McCaw, Lu Tian, et al.
Pageof 52

Showing results (171-180 of 520) with videos related to

Sort By:
Pageof 52
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Circulation|December 1, 2004
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) studyMariya P Tokmakova, Hicham Skali, Satish Kenchaiah, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|September 29, 2005
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM ProgramGary F Mitchell, J Malcolm O Arnold, Mark E Dunlap, et al.
European Journal of Heart Failure|March 1, 2014
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRTHicham Skali, Edward M Dwyer, Robert Goldstein, et al.
The American Journal of Cardiology|March 25, 2008
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitusNagesh S Anavekar, Scott D Solomon, John J V McMurray, et al.
European Journal of Heart Failure|October 1, 2022
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Brian L Claggett, Orly Vardeny, et al.
Hypertension (Dallas, Tex. : 1979)|December 12, 2007
Aortic diameter, wall stiffness, and wave reflection in systolic hypertensionGary F Mitchell, Paul R Conlin, Mark E Dunlap, et al.
NEJM Evidence|August 30, 2023
Quantifying Treatment Effects in Trials with Multiple Event-Time OutcomesBrian Lee Claggett, Zachary R McCaw, Lu Tian, et al.
Pageof 52